Skip to main content
An official website of the United States government

Government Funding Lapse

Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit  cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at OPM.gov.

Program Official
Principal Investigator
Samuel J. Milanovich
Awardee Organization

Sanford Research/Usd
United States

Fiscal Year
2025
Activity Code
UG1
Early Stage Investigator Grants (ESI)
Not Applicable
Project End Date

Sanford Community Cancer Program of the North Central Plains (NCORP)

Sanford Research, a non-profit research institution within Sanford Health, is dedicated to improving cancer outcomes through scientific discovery, clinical innovation, and broad community engagement. Serving one of the largest rural healthcare networks in the United States, Sanford Research is uniquely positioned to enhance the mission of the NCI Community Oncology Research Program (NCORP) by expanding access to cutting-edge cancer clinical trials, prevention strategies, and cancer care delivery research across rural, urban, and geographically dispersed populations.  Sanford Health spans over 250,000 square miles across the Upper Midwest, including North Dakota, South Dakota, Minnesota, Iowa, and rural communities in Montana and Nebraska. With more than 80 oncology providers across a network of more than 50 affiliated sites, Sanford has a well-established infrastructure for clinical trial implementation, regulatory compliance, and patient navigation. Sanford Research integrates seamlessly with Sanford’s clinical operations to streamline the activation, accrual, and management of NCI-sponsored trials.  Sanford has demonstrated strong performance in enrolling patients in oncology trials.  Through continued participation in NCORP, Sanford Research will build upon its existing foundation to expand research in cancer prevention and control, survivorship, and cancer care delivery science. Special emphasis will be placed on recruiting participants from rural populations to ensure broader representation in cancer research. Sanford’s multidisciplinary research teams—including epidemiologists, behavioral scientists, and clinical investigators—are prepared to contribute to NCORP’s national priorities while supporting meaningful local impact through community partnerships, patient-centered outreach, and data-driven care improvements.  Through this collaboration, Sanford Research aims to drive innovation and access in oncology care—furthering the NCORP mission and improving outcomes for patients in our communities through clinical research.

Publications

  • Bhatia AK, Lee JW, Pinto HA, Jacobs CD, Limburg PJ, Rubin P, Arusell RM, Dunphy EP, Khandekar JD, Reiner SA, Baez-Diaz L, Celano P, Li S, Li Y, Burtness BA, Adams GL, Pandya KJ. Double-blind, randomized phase 3 trial of low-dose 13-cis retinoic acid in the prevention of second primaries in head and neck cancer: Long-term follow-up of a trial of the Eastern Cooperative Oncology Group-ACRIN Cancer Research Group (C0590). Cancer. 2017 Dec 1;123(23):4653-4662. Epub 2017 Aug 7. PMID: 28786105